BFW 08/24 16:07 Roche Agrees to Buy Intermune in $8.3b Transaction
BN 08/24 16:05 *ROCHE AGREES TO BUY INTERMUNE IN $8.3B TRANSACTION
BN 08/24 16:05 *ROCHE AGREES TO BUY INTERMUNE IN $8.3B TRANSACTION
MORE: Roche Agrees to Buy InterMune in $8.3b Transaction
2014-08-24 16:17:45.71 GMT
By Andrea Snyder
Aug. 24 (Bloomberg) -- Transaction to be neutral to core
EPS in 2015, accretive from 2016 onwards.
* Transaction to close this year
* InterMune board recommends holders tender shrs to Roche
* Offer represents premium of 38% to InterMune’s closing price
on Aug. 22
* Citi is financial adviser to Roche; Centerview Partners,
Goldman Sachs financial advisers to InterMune
* NOTE: InterMune’s lead medicine pirfenidone approved for
idiopathic pulmonary fibrosis in EU, Canada, under
regulatory review in U.S.
Statement Link:NSN NATJ433MSFLS <GO>
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Andrea Snyder in Washington at +1-202-624-1831 or
asnyder5@bloomberg.net
To contact the editors responsible for this story:
Andrea Snyder at +1-202-624-1831 or
asnyder5@bloomberg.net
2014-08-24 16:17:45.71 GMT
By Andrea Snyder
Aug. 24 (Bloomberg) -- Transaction to be neutral to core
EPS in 2015, accretive from 2016 onwards.
* Transaction to close this year
* InterMune board recommends holders tender shrs to Roche
* Offer represents premium of 38% to InterMune’s closing price
on Aug. 22
* Citi is financial adviser to Roche; Centerview Partners,
Goldman Sachs financial advisers to InterMune
* NOTE: InterMune’s lead medicine pirfenidone approved for
idiopathic pulmonary fibrosis in EU, Canada, under
regulatory review in U.S.
Statement Link:NSN NATJ433MSFLS <GO>
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Andrea Snyder in Washington at +1-202-624-1831 or
asnyder5@bloomberg.net
To contact the editors responsible for this story:
Andrea Snyder at +1-202-624-1831 or
asnyder5@bloomberg.net